-
1
-
-
34848873146
-
Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center
-
PID: 17909360
-
Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol. 2007;2(10):957–965.
-
(2007)
J Thorac Oncol.
, vol.2
, Issue.10
, pp. 957-965
-
-
Flores, R.M.1
Zakowski, M.2
Venkatraman, E.3
-
2
-
-
84867888906
-
Initial analysis of the International Association for the Study of Lung Cancer mesothelioma database
-
PID: 23070243
-
Rusch VW, Giroux D, Kennedy C, et al. Initial analysis of the International Association For the Study of Lung Cancer mesothelioma database. J Thorac Oncol. 2012;7(11):1631–1639.
-
(2012)
J Thorac Oncol.
, vol.7
, Issue.11
, pp. 1631-1639
-
-
Rusch, V.W.1
Giroux, D.2
Kennedy, C.3
-
3
-
-
0032952875
-
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients
-
COI: 1:STN:280:DyaK1M7gt1Ghug%3D%3D, PID: 9869758, discussion 63-55
-
Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117(1):54–63; discussion 63–55.
-
(1999)
J Thorac Cardiovasc Surg.
, vol.117
, Issue.1
, pp. 54-63
-
-
Sugarbaker, D.J.1
Flores, R.M.2
Jaklitsch, M.T.3
-
4
-
-
84856529768
-
A nuclear grading system is a strong predictor of survival in epithelioid diffuse malignant pleural mesothelioma
-
COI: 1:CAS:528:DC%2BC38XhslOksro%3D, PID: 21983936
-
Kadota K, Suzuki K, Colovos C, et al. A nuclear grading system is a strong predictor of survival in epithelioid diffuse malignant pleural mesothelioma. Mod Pathol. 2012;25(2):260–271.
-
(2012)
Mod Pathol.
, vol.25
, Issue.2
, pp. 260-271
-
-
Kadota, K.1
Suzuki, K.2
Colovos, C.3
-
5
-
-
79955481828
-
Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma
-
PID: 21358344
-
Kadota K, Suzuki K, Sima CS, Rusch VW, Adusumilli PS, Travis WD. Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma. J Thorac Oncol. 2011;6(5):896–904.
-
(2011)
J Thorac Oncol.
, vol.6
, Issue.5
, pp. 896-904
-
-
Kadota, K.1
Suzuki, K.2
Sima, C.S.3
Rusch, V.W.4
Adusumilli, P.S.5
Travis, W.D.6
-
6
-
-
77951894575
-
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy
-
COI: 1:CAS:528:DC%2BC3cXltFGhtr8%3D, PID: 20177021
-
Righi L, Papotti MG, Ceppi P, et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol. 2010;28(9):1534–1539.
-
(2010)
J Clin Oncol.
, vol.28
, Issue.9
, pp. 1534-1539
-
-
Righi, L.1
Papotti, M.G.2
Ceppi, P.3
-
7
-
-
84858272601
-
Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation
-
COI: 1:CAS:528:DC%2BC38XktVynurc%3D, PID: 22261806
-
Burt BM, Bader A, Winter D, Rodig SJ, Bueno R, Sugarbaker DJ. Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation. Clin Cancer Res. 2012;18(6):1568–1577.
-
(2012)
Clin Cancer Res.
, vol.18
, Issue.6
, pp. 1568-1577
-
-
Burt, B.M.1
Bader, A.2
Winter, D.3
Rodig, S.J.4
Bueno, R.5
Sugarbaker, D.J.6
-
8
-
-
82355182060
-
Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients
-
COI: 1:CAS:528:DC%2BC3MXhsFantrrK, PID: 21769693
-
Suzuki K, Kadota K, Sima CS, et al. Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients. Cancer Immunol Immunother. 2011;60(12):1721–1728.
-
(2011)
Cancer Immunol Immunother.
, vol.60
, Issue.12
, pp. 1721-1728
-
-
Suzuki, K.1
Kadota, K.2
Sima, C.S.3
-
9
-
-
84862862536
-
High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology
-
PID: 22617244
-
Kadota K, Kachala SS, Nitadori J, et al. High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology. J Thorac Oncol. 2012;7(7):1192–1197.
-
(2012)
J Thorac Oncol.
, vol.7
, Issue.7
, pp. 1192-1197
-
-
Kadota, K.1
Kachala, S.S.2
Nitadori, J.3
-
10
-
-
0032952314
-
NCL-CD10-270: a new monoclonal antibody recognizing CD10 in paraffin-embedded tissue
-
COI: 1:CAS:528:DyaK1MXnsFCqtQ%3D%3D, PID: 9916921
-
McIntosh GG, Lodge AJ, Watson P, et al. NCL-CD10-270: a new monoclonal antibody recognizing CD10 in paraffin-embedded tissue. Am J Pathol. 1999;154(1):77–82.
-
(1999)
Am J Pathol.
, vol.154
, Issue.1
, pp. 77-82
-
-
McIntosh, G.G.1
Lodge, A.J.2
Watson, P.3
-
11
-
-
0027244148
-
Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key!
-
COI: 1:CAS:528:DyaK3sXms1yiurw%3D, PID: 8102558
-
Shipp MA, Look AT. Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key! Blood. 1993;82(4):1052–1070.
-
(1993)
Blood.
, vol.82
, Issue.4
, pp. 1052-1070
-
-
Shipp, M.A.1
Look, A.T.2
-
12
-
-
0030899822
-
Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX
-
COI: 1:CAS:528:DyaK2sXjtVWmtro%3D, PID: 9141502
-
Turner AJ, Tanzawa K. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J. 1997;11(5):355–364.
-
(1997)
FASEB J.
, vol.11
, Issue.5
, pp. 355-364
-
-
Turner, A.J.1
Tanzawa, K.2
-
13
-
-
0036329227
-
Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome
-
COI: 1:CAS:528:DC%2BD38XmsVWnt7o%3D, PID: 12070597
-
Iwaya K, Ogawa H, Izumi M, Kuroda M, Mukai K. Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome. Virchows Arch. 2002;440(6):589–593.
-
(2002)
Virchows Arch.
, vol.440
, Issue.6
, pp. 589-593
-
-
Iwaya, K.1
Ogawa, H.2
Izumi, M.3
Kuroda, M.4
Mukai, K.5
-
14
-
-
77951718259
-
Stromal CD10 expression and relationship to the E-cadherin/beta-catenin complex in breast carcinoma
-
PID: 20546336
-
Kim HS, Kim GY, Kim YW, Park YK, Song JY, Lim SJ. Stromal CD10 expression and relationship to the E-cadherin/beta-catenin complex in breast carcinoma. Histopathology. 2010;56(6):708–719.
-
(2010)
Histopathology.
, vol.56
, Issue.6
, pp. 708-719
-
-
Kim, H.S.1
Kim, G.Y.2
Kim, Y.W.3
Park, Y.K.4
Song, J.Y.5
Lim, S.J.6
-
15
-
-
84857096700
-
Characterization and clinical evaluation of CD10 + stroma cells in the breast cancer microenvironment
-
COI: 1:CAS:528:DC%2BC38XisVGhu74%3D, PID: 22235100
-
Desmedt C, Majjaj S, Kheddoumi N, et al. Characterization and clinical evaluation of CD10 + stroma cells in the breast cancer microenvironment. Clin Cancer Res. 2012;18(4):1004–1014.
-
(2012)
Clin Cancer Res.
, vol.18
, Issue.4
, pp. 1004-1014
-
-
Desmedt, C.1
Majjaj, S.2
Kheddoumi, N.3
-
16
-
-
26444506064
-
CD10 expression in colorectal carcinoma correlates with liver metastasis
-
PID: 16175325
-
Fujimoto Y, Nakanishi Y, Sekine S, et al. CD10 expression in colorectal carcinoma correlates with liver metastasis. Dis Colon Rectum. 2005;48(10):1883–1889.
-
(2005)
Dis Colon Rectum.
, vol.48
, Issue.10
, pp. 1883-1889
-
-
Fujimoto, Y.1
Nakanishi, Y.2
Sekine, S.3
-
17
-
-
77749318545
-
CD10 enhances metastasis of colorectal cancer by abrogating the anti-tumoural effect of methionine-enkephalin in the liver
-
COI: 1:CAS:528:DC%2BC3cXkvVOkur8%3D, PID: 19828468
-
Kuniyasu H, Luo Y, Fujii K, et al. CD10 enhances metastasis of colorectal cancer by abrogating the anti-tumoural effect of methionine-enkephalin in the liver. Gut. 2010;59(3):348–356.
-
(2010)
Gut.
, vol.59
, Issue.3
, pp. 348-356
-
-
Kuniyasu, H.1
Luo, Y.2
Fujii, K.3
-
18
-
-
80051808366
-
Prognostic role of CD10(+) myeloid cells in association with tumor budding at the invasion front of colorectal cancer
-
PID: 21599811
-
Khanh do T, Mekata E, Mukaisho K, et al. Prognostic role of CD10(+) myeloid cells in association with tumor budding at the invasion front of colorectal cancer. Cancer Sci. 2011;102(9):1724–1733.
-
(2011)
Cancer Sci.
, vol.102
, Issue.9
, pp. 1724-1733
-
-
Khanh do, T.1
Mekata, E.2
Mukaisho, K.3
-
19
-
-
33947409944
-
Differential expression of CD10 in prostate cancer and its clinical implication
-
PID: 17335564
-
Dall’Era MA, True LD, Siegel AF, Porter MP, Sherertz TM, Liu AY. Differential expression of CD10 in prostate cancer and its clinical implication. BMC Urol. 2007;7(1):3.
-
(2007)
BMC Urol.
, vol.7
, Issue.1
, pp. 3
-
-
Dall’Era, M.A.1
True, L.D.2
Siegel, A.F.3
Porter, M.P.4
Sherertz, T.M.5
Liu, A.Y.6
-
20
-
-
80051591478
-
High CD10 expression in lymph node metastases from surgically treated prostate cancer independently predicts early death
-
COI: 1:CAS:528:DC%2BC3MXmvFWns7o%3D, PID: 21538124
-
Fleischmann A, Rocha C, Saxer-Sekulic N, Zlobec I, Sauter G, Thalmann GN. High CD10 expression in lymph node metastases from surgically treated prostate cancer independently predicts early death. Virchows Arch. 2011;458(6):741–748.
-
(2011)
Virchows Arch.
, vol.458
, Issue.6
, pp. 741-748
-
-
Fleischmann, A.1
Rocha, C.2
Saxer-Sekulic, N.3
Zlobec, I.4
Sauter, G.5
Thalmann, G.N.6
-
21
-
-
84878523707
-
Prostate cancer cell phenotypes based on AGR2 and CD10 expression
-
COI: 1:CAS:528:DC%2BC3sXptVWmt7w%3D, PID: 23348903
-
Ho ME, Quek SI, True LD, et al. Prostate cancer cell phenotypes based on AGR2 and CD10 expression. Mod Pathol. 2013;26(6):849–859.
-
(2013)
Mod Pathol.
, vol.26
, Issue.6
, pp. 849-859
-
-
Ho, M.E.1
Quek, S.I.2
True, L.D.3
-
22
-
-
14844309613
-
CD10 and Bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses
-
COI: 1:STN:280:DC%2BD2M%2FptFOnuw%3D%3D, PID: 15720419
-
Biasoli I, Morais JC, Scheliga A, et al. CD10 and Bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses. Histopathology. 2005;46(3):328–333.
-
(2005)
Histopathology.
, vol.46
, Issue.3
, pp. 328-333
-
-
Biasoli, I.1
Morais, J.C.2
Scheliga, A.3
-
23
-
-
0345869698
-
Expression of bcl-6 and CD10 protein is associated with longer overall survival and time to treatment failure in follicular lymphoma
-
PID: 14750238
-
Bilalovic N, Blystad AK, Golouh R, et al. Expression of bcl-6 and CD10 protein is associated with longer overall survival and time to treatment failure in follicular lymphoma. Am J Clin Pathol. 2004;121(1):34–42.
-
(2004)
Am J Clin Pathol.
, vol.121
, Issue.1
, pp. 34-42
-
-
Bilalovic, N.1
Blystad, A.K.2
Golouh, R.3
-
24
-
-
33745019181
-
Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma
-
COI: 1:CAS:528:DC%2BD28XmsVarsbk%3D, PID: 16740034
-
Butnor KJ, Nicholson AG, Allred DC, et al. Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma. Arch Pathol Lab Med. 2006;130(6):823–827.
-
(2006)
Arch Pathol Lab Med.
, vol.130
, Issue.6
, pp. 823-827
-
-
Butnor, K.J.1
Nicholson, A.G.2
Allred, D.C.3
-
26
-
-
84864542897
-
A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma
-
PID: 22499226
-
Kadota K, Suzuki K, Kachala SS, et al. A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. Mod Pathol. 2012;25(8):1117–1127.
-
(2012)
Mod Pathol.
, vol.25
, Issue.8
, pp. 1117-1127
-
-
Kadota, K.1
Suzuki, K.2
Kachala, S.S.3
-
27
-
-
74949114784
-
Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer
-
COI: 1:CAS:528:DC%2BC3cXotF2k, PID: 20008839
-
Yoshizawa A, Fukuoka J, Shimizu S, et al. Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. Clin Cancer Res. 2010;16(1):240–248.
-
(2010)
Clin Cancer Res.
, vol.16
, Issue.1
, pp. 240-248
-
-
Yoshizawa, A.1
Fukuoka, J.2
Shimizu, S.3
-
28
-
-
84874792010
-
Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor beta2 (IL-12Rbeta2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence
-
COI: 1:CAS:528:DC%2BC3sXis1Skur8%3D, PID: 23269987
-
Suzuki K, Kadota K, Sima CS, et al. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor beta2 (IL-12Rbeta2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. J Clin Oncol. 2013;31(4):490–498.
-
(2013)
J Clin Oncol.
, vol.31
, Issue.4
, pp. 490-498
-
-
Suzuki, K.1
Kadota, K.2
Sima, C.S.3
-
29
-
-
0041629528
-
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
-
COI: 1:CAS:528:DC%2BD2cXptlCktL4%3D, PID: 12860938
-
Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–2644.
-
(2003)
J Clin Oncol.
, vol.21
, Issue.14
, pp. 2636-2644
-
-
Vogelzang, N.J.1
Rusthoven, J.J.2
Symanowski, J.3
-
30
-
-
67650002101
-
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma
-
COI: 1:CAS:528:DC%2BD1MXoslyisLo%3D, PID: 19364962
-
Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27(18):3007–3013.
-
(2009)
J Clin Oncol.
, vol.27
, Issue.18
, pp. 3007-3013
-
-
Krug, L.M.1
Pass, H.I.2
Rusch, V.W.3
-
31
-
-
84905277260
-
CD10 as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma
-
COI: 1:CAS:528:DC%2BC2cXovFCls7s%3D, PID: 24874475
-
Fukusumi T, Ishii H, Konno M, et al. CD10 as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma. Br J Cancer. 2014;111(3):506–514.
-
(2014)
Br J Cancer.
, vol.111
, Issue.3
, pp. 506-514
-
-
Fukusumi, T.1
Ishii, H.2
Konno, M.3
-
32
-
-
39749186005
-
Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin
-
COI: 1:CAS:528:DC%2BD1cXhvF2nt7o%3D, PID: 18281561
-
Ravel D, Dubois V, Quinonero J, et al. Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin. Clin Cancer Res. 2008;14(4):1258–1265.
-
(2008)
Clin Cancer Res.
, vol.14
, Issue.4
, pp. 1258-1265
-
-
Ravel, D.1
Dubois, V.2
Quinonero, J.3
-
33
-
-
0141592792
-
CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10(+) tumors
-
COI: 1:CAS:528:DC%2BD3sXntlersr0%3D, PID: 14500390
-
Pan C, Cardarelli PM, Nieder MH, et al. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10(+) tumors. Cancer Res. 2003;63(17):5526–5531.
-
(2003)
Cancer Res.
, vol.63
, Issue.17
, pp. 5526-5531
-
-
Pan, C.1
Cardarelli, P.M.2
Nieder, M.H.3
-
34
-
-
79251559363
-
Valproate-doxorubicin: promising therapy for progressing mesothelioma: a phase II study
-
COI: 1:CAS:528:DC%2BC3MXjvVWhtro%3D, PID: 20530048
-
Scherpereel A, Berghmans T, Lafitte JJ, et al. Valproate-doxorubicin: promising therapy for progressing mesothelioma: a phase II study. Eur Respir J. 2011;37(1):129–135.
-
(2011)
Eur Respir J.
, vol.37
, Issue.1
, pp. 129-135
-
-
Scherpereel, A.1
Berghmans, T.2
Lafitte, J.J.3
-
35
-
-
84858280990
-
First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial
-
COI: 1:CAS:528:DC%2BC38XktVait7k%3D, PID: 22353806
-
Arrieta O, Medina LA, Estrada-Lobato E, et al. First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial. Br J Cancer. 2012;106(6):1027–1032.
-
(2012)
Br J Cancer.
, vol.106
, Issue.6
, pp. 1027-1032
-
-
Arrieta, O.1
Medina, L.A.2
Estrada-Lobato, E.3
|